Billionaire Profile
Wolfgang Marguerre & family
Global Rank
#459

Image: Unsplash Contributor | Unsplash License | via Unsplash

Wolfgang Marguerre & family

CEO, Pharmaceuticals
GERMANY
Real-Time Net Worth
$7.916B
Estimated based on Pharmaceuticals stock value as of April 21, 2026
0% (24h)
Age
85
Source
Pharmaceuticals
Industry
Healthcare
Citizenship
GERMANY

Biography

Wolfgang Marguerre, a German billionaire, is the founder and chairman of Octapharma AG, a global healthcare company specializing in plasma-derived therapies. Born in Heidelberg, Germany, in 1941, Marguerre earned an MBA from INSEAD. His career began in pharmaceuticals in 1975, and he founded Octapharma in 1983. Under his leadership, Octapharma has become a major player in the biopharmaceutical industry, with a focus on treatments for hemophilia, immune deficiencies, and critical care. His net worth is estimated at $7.9 billion, and his contributions extend to significant philanthropic initiatives, particularly in education and support for individuals with bleeding disorders.

Fact Checked
Verified by Editorial Team
Live Data
Updated 4/21/2026

Wealth Over Time

In-Depth Profile

Early Life

Wolfgang Marguerre was born in Heidelberg, Germany, on January 30, 1941. He grew up in Heidelberg during the post-World War II period. His early life was marked by an emphasis on education, which later influenced his entrepreneurial pursuits. He studied Political and Economic Science at Heidelberg University and obtained an MBA from INSEAD in 1972.

Rise to Success

Marguerre's career in the pharmaceutical industry began in 1975 at Baxter's Travenol Laboratories, where he managed the plasma derivatives business. In 1978, he became Senior Executive Vice President of Revlon Healthcare Group. In 1983, he founded Octapharma in Switzerland. The company initially focused on developing safer and improved plasma-derived therapies for hemophilia patients. Octapharma has since grown into a global biopharmaceutical leader, manufacturing products for hematology, immunology, and critical care.

Key Business Strategies

Octapharma's success stems from a focus on high-quality plasma fractionation. The company expanded its manufacturing capabilities through strategic acquisitions and built state-of-the-art facilities. Key strategies include innovation in therapies, global expansion, and an emphasis on patient care and medical advancement.

Philanthropy

Marguerre is involved in various philanthropic endeavors, primarily supporting education and medical initiatives. He founded the Octapharma Scholarship at INSEAD, providing financial assistance to MBA students. He also sponsors children with bleeding disorders through Save One Life, aligning with Octapharma's focus on therapies for rare diseases. He has donated $17.5 million to renovate Theater Heidelberg and $1.13 million to support refugee integration in Heidelberg.

Career Milestones

1975

Manager of plasma derivatives business at Baxter's Travenol Laboratories

Began career in the pharmaceutical sector, developing expertise in plasma-based products.

1978

Senior Executive Vice President of Revlon Healthcare Group

Assumed leadership responsibilities within the plasma division.

1983

Founded Octapharma AG

Established Octapharma with a focus on safer therapies for hemophilia patients.

2009

Awarded the Légion d'honneur

Received the highest decoration bestowed by France.

2011

Awarded the Gold Decoration of Honour for Services to the Republic of Austria

Recognized for contributions to the pharmaceutical industry.

Philanthropy & Social Impact

Education

Octapharma Scholarship

$25K (per student)

Supports MBA students from various countries.

Medical

Save One Life

Undisclosed

Sponsors children with bleeding disorders.

Arts

Heidelberg Theater Renovation

$17.5M

Donation for the renovation of the Theater Heidelberg.

Social Services

Refugee Integration

$1.13M

Supports the integration of refugees in Heidelberg.

Business Philosophy & Leadership

Notable Quotes

"We must never allow ourselves to become complacent, or to think that we have achieved "enough.""

Leadership Principles

Innovation

Commitment to research and development of new therapies.

Accessibility

Expanding access to therapies for more patients worldwide.

Responsibility

Ensuring the safe and optimal use of human proteins.

Controversies & Challenges

2017

Allegations of Targeting Vulnerable Populations

Accusations of targeting unemployed and drug-addicted individuals in the U.S. for plasma donation, risking their health.